Jim Cramer
-
Health News
Why Pfizer’s latest stumble in the obesity market is a boon for Eli Lilly
[ad_1] Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news…
Read More » -
Health News
The sell-off in Humana is overdone after strong earnings. Jim Cramer says buy the stock
[ad_1] The post-earnings decline in Humana (HUM) shares Wednesday was overdone, providing investors an opportunity to add to their positions…
Read More » -
Health News
We’re buying more of this life sciences stock after an earnings-driven decline
[ad_1] The stock is under pressure in early trading due to uncertainty around the recovery in a key business. [ad_2]
Read More » -
Health News
When is it OK to violate your cost basis to buy more shares of a company?
[ad_1] Here’s our Club Mailbag email investingclubmailbag@cnbc.com — so you send your questions directly to Jim Cramer and his team…
Read More » -
Health News
Here are 3 stocks in our portfolio that Goldman Sachs think will rally on earnings
[ad_1] It’s encouraging to see three Club stocks on the bullish side of Goldman Sachs’ new list of 25 tactical…
Read More » -
Health News
15 stocks with a history of dividend growth are expected to deliver once again this year
[ad_1] Broadcom (AVGO), Caterpillar (CAT) and Eli Lilly (LLY) are among the 15 Club stocks with a streak of annual…
Read More » -
Health News
Cramer says Vertex has a drug that may address the ‘largest market opportunity in the world’
[ad_1] CNBC’s Jim Cramer on Monday suggested that investors keep an eye on Vertex Pharmaceuticals (VRTX), a biotechnology company developing…
Read More »